Search
Arcutis Biotherapeutics Inc
ARQTAdd to Watchlist
26.250USD
+0.030+0.11%
Market hours （ET）Quotes delayed by 15 min
3.28BMarket Cap
LossP/E TTM
More Details of Arcutis Biotherapeutics Inc Company
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Arcutis Biotherapeutics Inc Info
Ticker SymbolARQT
Company nameArcutis Biotherapeutics Inc
IPO dateJan 31, 2020
CEOWatanabe (Todd Franklin)
Number of employees342
Security typeOrdinary Share
Fiscal year-endJan 31
Address3027 Townsgate Road
CityWESTLAKE VILLAGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91361
Phone18054185006
Websitehttps://arcutis.com/
Ticker SymbolARQT
IPO dateJan 31, 2020
CEOWatanabe (Todd Franklin)
Company Executives of Arcutis Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.83%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
687.27K
-0.46%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
83.36K
+6.93%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
39.95K
-20.67%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
37.74K
+13.63%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
27.90K
+20.71%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.77K
-6.40%
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
27.57K
+3.02%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Dr. Patrick E. Burnett, M.D., Ph.D.
Dr. Patrick E. Burnett, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.83%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
687.27K
-0.46%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
83.36K
+6.93%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
39.95K
-20.67%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
37.74K
+13.63%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
27.90K
+20.71%
FAQs
Who are the top five shareholders of Arcutis Biotherapeutics Inc?
The top five shareholders of Arcutis Biotherapeutics Inc are: Dr. Bhaskar Chaudhuri, Ph.D.
How many institutions hold shares of Arcutis Biotherapeutics Inc (ARQT)?
As of 2026Q1, 557 institutions hold shares of Arcutis Biotherapeutics Inc, with a combined market value of approximately 133.41M, accounting for 106.66% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -7502176.00.